Nabriva Therapeutics AG (NASDAQ:NBRV) has received an average rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $15.17.
Several brokerages have issued reports on NBRV. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a research note on Friday, June 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Nabriva Therapeutics AG in a research report on Friday, June 23rd. ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Saturday, May 27th. Finally, Wedbush reaffirmed an “outperform” rating and set a $13.00 target price on shares of Nabriva Therapeutics AG in a research report on Monday, May 15th.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Nabriva Therapeutics AG (NASDAQ:NBRV) PT at $15.17” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.wkrb13.com/markets/2285826/analysts-set-nabriva-therapeutics-ag-nasdaqnbrv-pt-at-15-17.html.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $10.52, for a total transaction of $28,351.40. Following the transaction, the insider now directly owns 2,569,315 shares of the company’s stock, valued at $27,029,193.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director George Harrison Talbot sold 325 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total transaction of $32,682.00. Following the transaction, the director now directly owns 3,854 shares in the company, valued at $387,558.24. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,434 shares of company stock worth $1,220,025.
A number of institutional investors have recently modified their holdings of NBRV. Renaissance Technologies LLC acquired a new position in shares of Nabriva Therapeutics AG during the fourth quarter valued at about $103,000. Nationwide Fund Advisors acquired a new position in shares of Nabriva Therapeutics AG during the first quarter valued at about $2,074,000. Wellington Management Group LLP raised its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the last quarter. Finally, Almanack Investment Partners LLC. acquired a new position in shares of Nabriva Therapeutics AG during the first quarter valued at about $1,870,000. 55.90% of the stock is currently owned by institutional investors.
Shares of Nabriva Therapeutics AG (NBRV) traded up 1.90% on Friday, reaching $10.70. The company had a trading volume of 913 shares. The firm’s market capitalization is $29.11 million. The stock’s 50 day moving average is $9.87 and its 200 day moving average is $9.52. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $12.75.
About Nabriva Therapeutics AG
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285826/analysts-set-nabriva-therapeutics-ag-nasdaqnbrv-pt-at-15-17.html
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.